#1 Clinical Trials Search in Europe

Secale Cereale

This article discusses the use of Secale Cereale, commonly known as rye, in clinical trials for allergy treatment. Secale Cereale is one of several grass pollens being studied as part of a mixture for skin prick tests and potential immunotherapy for allergic rhinitis and rhinoconjunctivitis caused by house dust mite allergies. The trials aim to assess the effectiveness and safety of these treatments in managing allergy symptoms and improving patients’ quality of life.

Table of Contents

What is SECALE CEREALE?

SECALE CEREALE, also known as rye, is a type of grass pollen that is being studied for its potential use in allergy treatments[1]. It is one of several grass pollens included in a mixture being tested for allergen immunotherapy, which is a treatment aimed at reducing allergic reactions in people with certain types of allergies.

Medical Uses

SECALE CEREALE is primarily being investigated for its use in treating allergic rhinitis and rhinoconjunctivitis caused by grass pollen allergies[1]. These conditions involve symptoms such as:

  • Sneezing
  • Runny or stuffy nose
  • Itchy or watery eyes
  • Itchy throat or ears

The treatment containing SECALE CEREALE is being studied specifically for people with moderate to severe symptoms who may also have asthma related to their grass pollen allergy[1].

How It Works

SECALE CEREALE is used as part of allergen immunotherapy. This type of treatment works by exposing the body to small amounts of the allergen (in this case, grass pollen) over time. The goal is to help the immune system become less sensitive to the allergen, reducing allergic reactions when the person is exposed to grass pollen in their environment[1].

Administration

In the study mentioned, SECALE CEREALE is being administered as part of a mixture of grass pollens in a solution for skin-prick tests[1]. However, for actual treatment, it would likely be given as a subcutaneous injection (an injection under the skin). The treatment typically involves an initial phase of increasing doses, followed by a maintenance phase with regular injections over an extended period.

Potential Benefits

If proven effective, treatment with SECALE CEREALE as part of a grass pollen mixture could potentially:

  • Reduce the severity of allergy symptoms
  • Decrease the need for allergy medications
  • Improve quality of life for people with grass pollen allergies
  • Potentially prevent the development of asthma in some individuals with allergic rhinitis

Safety and Side Effects

As with any medical treatment, there are potential risks and side effects associated with allergen immunotherapy. These may include:

  • Local reactions at the injection site (redness, swelling, itching)
  • Systemic allergic reactions (in rare cases)
  • Worsening of asthma symptoms (in individuals with asthma)

It’s important to note that allergen immunotherapy should only be administered under the supervision of a qualified healthcare professional, typically an allergist[1].

Ongoing Research

The information about SECALE CEREALE comes from a clinical trial studying its use as part of a grass pollen mixture for allergen immunotherapy[1]. This research aims to assess the effectiveness and safety of this treatment for people with moderate to severe allergic rhinitis or rhinoconjunctivitis caused by grass pollen allergies.

The study is evaluating various aspects of the treatment, including:

  • Its effect on allergy symptoms
  • The need for allergy medications
  • Changes in quality of life
  • Safety and tolerability of the treatment
  • Its impact on asthma in participants who have both allergies and asthma

It’s important to remember that while this research is promising, SECALE CEREALE as part of this specific treatment is still under investigation. More studies may be needed before it becomes widely available as a treatment option.

Aspect Details
Study Type Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study
Main Objective Assess efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy
Target Condition Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
Primary Endpoint Average daily Total Combined Rhinitis Score (TCRS) during the last 8 weeks of treatment
Key Inclusion Criteria Age 18-65, history of HDM allergic rhinitis, positive skin prick test, elevated specific IgE levels
Key Exclusion Criteria Severe immune disorders, uncontrolled asthma, recent immunotherapy
Treatment Duration Approximately 52 weeks
Safety Assessments Adverse events, local and systemic reactions, asthma-related parameters

FAQ

  • What is Secale Cereale and how is it used in allergy treatment? Secale Cereale is the scientific name for rye, a type of grass. In allergy treatment, it is used as one component in a mixture of grass pollens for skin prick tests and potential immunotherapy. These treatments aim to help diagnose and manage allergies, particularly those related to grass pollen.
  • What conditions are being studied in the clinical trials involving Secale Cereale? The clinical trials are focusing on moderate to severe allergic rhinitis and rhinoconjunctivitis, with or without asthma, induced by house dust mite (HDM) allergies. The studies aim to assess the effectiveness of immunotherapy treatments that include Secale Cereale as part of a grass pollen mixture.
  • How is the effectiveness of the treatment measured in these trials? The effectiveness is primarily measured using the Total Combined Rhinitis Score (TCRS), which assesses nasal symptoms and medication use. Other measures include the Total Nasal Symptom Score (TNSS), Rhinitis Medication Score (RMS), and quality of life questionnaires.
  • Are there any specific eligibility criteria for participating in these trials? Yes, participants must be between 18-65 years old, have a history of moderate to severe HDM allergic rhinitis for at least one year, show positive skin prick tests to house dust mites, have elevated specific IgE levels, and meet certain symptom severity criteria. There are also several exclusion criteria, such as severe immune disorders or uncontrolled asthma.
  • What are the potential benefits and risks of participating in these clinical trials? Potential benefits include improved management of allergy symptoms and better quality of life. Risks may include treatment-related adverse events, local and systemic reactions to the immunotherapy. The trials closely monitor safety and tolerability, including effects on asthma parameters for participants with asthma.

Ongoing Clinical Trials on Secale Cereale

  • Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Bulgaria Germany Latvia Lithuania Poland

Glossary

  • Allergic Rhinitis: An allergic reaction that causes inflammation in the nose, leading to symptoms such as sneezing, itching, and congestion.
  • Rhinoconjunctivitis: A combination of rhinitis (nasal symptoms) and conjunctivitis (eye symptoms) caused by allergies.
  • House Dust Mite (HDM): Tiny insects that commonly live in household dust and can cause allergic reactions in some people.
  • Immunotherapy: A treatment that aims to change the immune system's response to allergens, potentially reducing allergy symptoms over time.
  • Skin Prick Test (SPT): A method used to diagnose allergies by applying small amounts of allergens to the skin and observing the reaction.
  • Total Combined Rhinitis Score (TCRS): A measure used to assess the severity of rhinitis symptoms and medication use in allergy studies.
  • IgE (Immunoglobulin E): An antibody produced by the immune system that plays a key role in allergic reactions.
  • Forced Expiratory Volume 1 (FEV1): A measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • Nasal Provocation Test (NPT): A test used to diagnose nasal allergies by applying allergens directly to the nasal passages and observing the reaction.
  • ARIA classification: Allergic Rhinitis and its Impact on Asthma, a system used to classify the severity and duration of allergic rhinitis symptoms.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-purethal-mites-for-adults-with-moderate-to-severe-allergic-rhinitis-or-rhinoconjunctivitis-due-to-house-dust-mite-allergy/